JP2014523887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523887A5 JP2014523887A5 JP2014517431A JP2014517431A JP2014523887A5 JP 2014523887 A5 JP2014523887 A5 JP 2014523887A5 JP 2014517431 A JP2014517431 A JP 2014517431A JP 2014517431 A JP2014517431 A JP 2014517431A JP 2014523887 A5 JP2014523887 A5 JP 2014523887A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- butyl
- butoxy
- butylamino
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 hydroxy, mercapto, cyano, amino Chemical group 0.000 claims description 810
- 150000001875 compounds Chemical class 0.000 claims description 218
- 239000001257 hydrogen Substances 0.000 claims description 135
- 229910052739 hydrogen Inorganic materials 0.000 claims description 135
- 150000002431 hydrogen Chemical group 0.000 claims description 111
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 107
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 99
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 95
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 94
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 94
- 125000003282 alkyl amino group Chemical group 0.000 claims description 88
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 84
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 77
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 77
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 69
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 56
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 54
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 53
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 48
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 48
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 47
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 47
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 47
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 47
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 47
- 125000001153 fluoro group Chemical group F* 0.000 claims description 47
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 47
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 150000001336 alkenes Chemical class 0.000 claims description 34
- 125000004442 acylamino group Chemical group 0.000 claims description 32
- 125000004423 acyloxy group Chemical group 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 30
- 150000002148 esters Chemical class 0.000 claims description 29
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- UNLBRWACURAHRZ-UHFFFAOYSA-N oxo-[[1-[[5-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methyl]thiophen-2-yl]methyl]pyridin-4-ylidene]methyl]azanium;diperchlorate Chemical group [O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.C1=CC(=C[NH+]=O)C=CN1CC(S1)=CC=C1CN1C=CC(=C[NH+]=O)C=C1 UNLBRWACURAHRZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000011593 sulfur Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 2
- BUYUFJZVMVFQLQ-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydroquinoxalin-2-yl)ethynyl]benzoic acid Chemical compound CC1(C=2N=CC(=NC=2C(CC1)(C)C)C#CC1=CC=C(C(=O)O)C=C1)C BUYUFJZVMVFQLQ-UHFFFAOYSA-N 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 125000006309 butyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 218
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 186
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 147
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 147
- 238000002360 preparation method Methods 0.000 description 140
- 239000011734 sodium Substances 0.000 description 133
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 123
- 239000000203 mixture Substances 0.000 description 114
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 112
- 229910052753 mercury Inorganic materials 0.000 description 112
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 101
- 238000010992 reflux Methods 0.000 description 81
- 235000019439 ethyl acetate Nutrition 0.000 description 73
- 239000000460 chlorine Substances 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 238000010898 silica gel chromatography Methods 0.000 description 58
- 239000012043 crude product Substances 0.000 description 56
- 239000007787 solid Substances 0.000 description 54
- 230000007935 neutral effect Effects 0.000 description 50
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 48
- 239000012044 organic layer Substances 0.000 description 46
- 239000006188 syrup Substances 0.000 description 43
- 235000020357 syrup Nutrition 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 34
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 32
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 29
- 239000002198 insoluble material Substances 0.000 description 29
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 29
- 239000012153 distilled water Substances 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000012267 brine Substances 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 23
- 239000008346 aqueous phase Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 239000008096 xylene Substances 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000007810 chemical reaction solvent Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 150000001299 aldehydes Chemical class 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 239000003638 chemical reducing agent Substances 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 9
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 9
- 229960004592 isopropanol Drugs 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 8
- 150000003871 sulfonates Chemical class 0.000 description 8
- 0 *C(CC(CO)(CO)N)c1ccc(*c(cc2)ccc2-c2ncc[s]2)cc1 Chemical compound *C(CC(CO)(CO)N)c1ccc(*c(cc2)ccc2-c2ncc[s]2)cc1 0.000 description 7
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 7
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical group Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000001769 aryl amino group Chemical group 0.000 description 6
- 238000006482 condensation reaction Methods 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- RVYNIIJBIAINNT-UHFFFAOYSA-N propane-1,3-diol;hydrochloride Chemical compound Cl.OCCCO RVYNIIJBIAINNT-UHFFFAOYSA-N 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- KXYJNSJYQCRPRE-UHFFFAOYSA-N 2-chloro-1-(4-phenoxyphenyl)ethanone Chemical compound C1=CC(C(=O)CCl)=CC=C1OC1=CC=CC=C1 KXYJNSJYQCRPRE-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 3
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- RSYWMSKMNWLWCR-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-(2-chloroacetyl)phenyl]sulfanylphenyl]-2-oxoethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Sc2ccc(cc2)C(=O)CCl)cc1)(NC(C)=O)C(=O)OCC RSYWMSKMNWLWCR-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000011968 lewis acid catalyst Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 2
- BOLBVKKULUWVLA-UHFFFAOYSA-N 1-[4-(4-butylphenyl)sulfanylphenyl]-2-chloroethanone Chemical compound C1=CC(CCCC)=CC=C1SC1=CC=C(C(=O)CCl)C=C1 BOLBVKKULUWVLA-UHFFFAOYSA-N 0.000 description 2
- GAPYMIKIYFGGKP-UHFFFAOYSA-N 1-butyl-4-phenoxybenzene Chemical compound C1=CC(CCCC)=CC=C1OC1=CC=CC=C1 GAPYMIKIYFGGKP-UHFFFAOYSA-N 0.000 description 2
- XUSJZDVQXFACQB-UHFFFAOYSA-N 2-(4-phenoxyphenyl)pyrimidine Chemical compound C=1C=C(C=2N=CC=CN=2)C=CC=1OC1=CC=CC=C1 XUSJZDVQXFACQB-UHFFFAOYSA-N 0.000 description 2
- OOQOLDCNVQPKMA-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-cyclopropyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(CCC(CO)(CO)N)=CC=C1SC1=CC=C(C=2N=C(OC=2)C2CC2)C=C1 OOQOLDCNVQPKMA-UHFFFAOYSA-N 0.000 description 2
- IPFXRQFOZSBJOG-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(CC)=NC(C=2C=CC(SC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 IPFXRQFOZSBJOG-UHFFFAOYSA-N 0.000 description 2
- SOEVRWLYZBWPEF-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-ethyl-1h-imidazol-5-yl)phenoxy]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.N1C(CC)=NC=C1C(C=C1)=CC=C1OC1=CC=C(CCC(N)(CO)CO)C=C1 SOEVRWLYZBWPEF-UHFFFAOYSA-N 0.000 description 2
- KICNBGFWAYSXGV-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-propan-2-yl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(C(C)C)=NC(C=2C=CC(SC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 KICNBGFWAYSXGV-UHFFFAOYSA-N 0.000 description 2
- JFKILTNRWHBAGM-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-propyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(CCC)=NC(C=2C=CC(SC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 JFKILTNRWHBAGM-UHFFFAOYSA-N 0.000 description 2
- ZNEICPBUNLXMCP-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(5-methyl-1h-pyrrol-2-yl)phenoxy]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.N1C(C)=CC=C1C(C=C1)=CC=C1OC1=CC=C(CCC(N)(CO)CO)C=C1 ZNEICPBUNLXMCP-UHFFFAOYSA-N 0.000 description 2
- LVZJYJYBIHSUCM-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(5-methylfuran-2-yl)phenoxy]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(C)=CC=C1C(C=C1)=CC=C1OC1=CC=C(CCC(N)(CO)CO)C=C1 LVZJYJYBIHSUCM-UHFFFAOYSA-N 0.000 description 2
- YDNSBWROHRZRIF-UHFFFAOYSA-N 2-bromo-1-[4-(4-pyrimidin-2-ylphenoxy)phenyl]ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1OC1=CC=C(C=2N=CC=CN=2)C=C1 YDNSBWROHRZRIF-UHFFFAOYSA-N 0.000 description 2
- BRQAZRFENCXPBD-UHFFFAOYSA-N 2-bromo-1-[4-[4-(5-methyl-1,3-thiazol-2-yl)phenoxy]phenyl]ethanone Chemical compound S1C(C)=CN=C1C(C=C1)=CC=C1OC1=CC=C(C(=O)CBr)C=C1 BRQAZRFENCXPBD-UHFFFAOYSA-N 0.000 description 2
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
- MJSOAOFVJMDJJP-UHFFFAOYSA-N 2-chloro-1-(4-phenylsulfanylphenyl)ethanone Chemical compound C1=CC(C(=O)CCl)=CC=C1SC1=CC=CC=C1 MJSOAOFVJMDJJP-UHFFFAOYSA-N 0.000 description 2
- GWSTUUNCARBYBG-UHFFFAOYSA-N 2-ethylbutanamide;propanedioic acid Chemical compound OC(=O)CC(O)=O.CCC(CC)C(N)=O GWSTUUNCARBYBG-UHFFFAOYSA-N 0.000 description 2
- VTOONGZEPRFCJX-UHFFFAOYSA-N 3-amino-1-[4-[4-(2-cyclopropyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)butane-1,4-diol;hydrochloride Chemical compound Cl.C1=CC(C(O)CC(CO)(CO)N)=CC=C1SC1=CC=C(C=2N=C(OC=2)C2CC2)C=C1 VTOONGZEPRFCJX-UHFFFAOYSA-N 0.000 description 2
- AYNISXMEHHDPBT-UHFFFAOYSA-N 3-amino-1-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(CC)=NC(C=2C=CC(SC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 AYNISXMEHHDPBT-UHFFFAOYSA-N 0.000 description 2
- GEXIMGGRRNDYGK-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-methyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(C)=NC(C=2C=CC(SC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 GEXIMGGRRNDYGK-UHFFFAOYSA-N 0.000 description 2
- ZLQDJTCQJPMVSZ-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-propan-2-yl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(C(C)C)=NC(C=2C=CC(SC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 ZLQDJTCQJPMVSZ-UHFFFAOYSA-N 0.000 description 2
- SZHCWIULLBZRBM-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-propyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(CCC)=NC(C=2C=CC(SC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 SZHCWIULLBZRBM-UHFFFAOYSA-N 0.000 description 2
- XXRQDYDLSZMMDW-UHFFFAOYSA-N 5-methyl-2-(4-phenoxyphenyl)-1,3-thiazole Chemical compound S1C(C)=CN=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XXRQDYDLSZMMDW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BXHAEBXENDGTHZ-UHFFFAOYSA-N Cc1cnc(-c(cc2)ccc2Oc2ccc(C(CC(CO)(CO)N)O)cc2)[s]1 Chemical compound Cc1cnc(-c(cc2)ccc2Oc2ccc(C(CC(CO)(CO)N)O)cc2)[s]1 BXHAEBXENDGTHZ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 206010021027 Hypomagnesaemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- OTFDIBZEMPIGLB-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-oxo-2-(4-phenylsulfanylphenyl)ethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Sc2ccccc2)cc1)(NC(C)=O)C(=O)OCC OTFDIBZEMPIGLB-UHFFFAOYSA-N 0.000 description 2
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BSVJPYZXRUVBEM-UHFFFAOYSA-N 1-butyl-4-phenylsulfanylbenzene Chemical compound C1=CC(CCCC)=CC=C1SC1=CC=CC=C1 BSVJPYZXRUVBEM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UABGXHZWFLSNNZ-UHFFFAOYSA-N 2-amino-2-[2-[4-(4-butylphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(CCCC)=CC=C1SC1=CC=C(CCC(N)(CO)CO)C=C1 UABGXHZWFLSNNZ-UHFFFAOYSA-N 0.000 description 1
- YPBQYWJQMZVEMG-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-cyclopropyl-1,3-oxazol-4-yl)phenoxy]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(CCC(CO)(CO)N)=CC=C1OC1=CC=C(C=2N=C(OC=2)C2CC2)C=C1 YPBQYWJQMZVEMG-UHFFFAOYSA-N 0.000 description 1
- VSQCCDGJJBIWHZ-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenoxy]phenyl]ethyl]propane-1,3-diol hydrochloride Chemical compound Cl.CCc1nc(co1)-c1ccc(Oc2ccc(CCC(N)(CO)CO)cc2)cc1 VSQCCDGJJBIWHZ-UHFFFAOYSA-N 0.000 description 1
- FAERRDGFAINHQI-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-methyl-1,3-oxazol-4-yl)phenoxy]phenyl]ethyl]propane-1,3-diol hydrochloride Chemical compound Cl.Cc1nc(co1)-c1ccc(Oc2ccc(CCC(N)(CO)CO)cc2)cc1 FAERRDGFAINHQI-UHFFFAOYSA-N 0.000 description 1
- LYVMEKYNYHJOTL-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-methyl-1,3-oxazol-4-yl)phenyl]sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(C)=NC(C=2C=CC(SC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 LYVMEKYNYHJOTL-UHFFFAOYSA-N 0.000 description 1
- DHCGEMXILWSOSE-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-propan-2-yl-1,3-oxazol-4-yl)phenoxy]phenyl]ethyl]propane-1,3-diol Chemical compound O1C(C(C)C)=NC(C=2C=CC(OC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 DHCGEMXILWSOSE-UHFFFAOYSA-N 0.000 description 1
- LRQOEDXDZIODQF-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2-propyl-1,3-oxazol-4-yl)phenoxy]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.O1C(CCC)=NC(C=2C=CC(OC=3C=CC(CCC(N)(CO)CO)=CC=3)=CC=2)=C1 LRQOEDXDZIODQF-UHFFFAOYSA-N 0.000 description 1
- FJPZHYAYNAUKKA-UHFFFAOYSA-N 2-bromo-5-methyl-1,3-thiazole Chemical compound CC1=CN=C(Br)S1 FJPZHYAYNAUKKA-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- RUXZDJAVUGTZOT-UHFFFAOYSA-N 3-amino-1-[4-(4-butylphenyl)sulfanylphenyl]-3-(hydroxymethyl)butane-1,4-diol;hydrochloride Chemical compound Cl.C1=CC(CCCC)=CC=C1SC1=CC=C(C(O)CC(N)(CO)CO)C=C1 RUXZDJAVUGTZOT-UHFFFAOYSA-N 0.000 description 1
- BRXTUSMJIDZHNP-UHFFFAOYSA-N 3-amino-1-[4-[4-(2-cyclopropyl-1,3-oxazol-4-yl)phenoxy]phenyl]-3-(hydroxymethyl)butane-1,4-diol;hydrochloride Chemical compound Cl.C1=CC(C(O)CC(CO)(CO)N)=CC=C1OC1=CC=C(C=2N=C(OC=2)C2CC2)C=C1 BRXTUSMJIDZHNP-UHFFFAOYSA-N 0.000 description 1
- HGEMIVPQXULUSS-UHFFFAOYSA-N 3-amino-1-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenoxy]phenyl]-3-(hydroxymethyl)butane-1,4-diol Chemical compound O1C(CC)=NC(C=2C=CC(OC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 HGEMIVPQXULUSS-UHFFFAOYSA-N 0.000 description 1
- QNFZZBIITJUOGJ-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-(4-pyrimidin-2-ylphenoxy)phenyl]butane-1,4-diol Chemical compound C1=CC(C(O)CC(CO)(CO)N)=CC=C1OC1=CC=C(C=2N=CC=CN=2)C=C1 QNFZZBIITJUOGJ-UHFFFAOYSA-N 0.000 description 1
- MZOAPRSWOQCMMY-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-methyl-1,3-oxazol-4-yl)phenoxy]phenyl]butane-1,4-diol Chemical compound O1C(C)=NC(C=2C=CC(OC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 MZOAPRSWOQCMMY-UHFFFAOYSA-N 0.000 description 1
- OTOGYJDCMZIFJV-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-propan-2-yl-1,3-oxazol-4-yl)phenoxy]phenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(C(C)C)=NC(C=2C=CC(OC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 OTOGYJDCMZIFJV-UHFFFAOYSA-N 0.000 description 1
- LOBMTDZTFKYKNO-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(2-propyl-1,3-oxazol-4-yl)phenoxy]phenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.O1C(CCC)=NC(C=2C=CC(OC=3C=CC(=CC=3)C(O)CC(N)(CO)CO)=CC=2)=C1 LOBMTDZTFKYKNO-UHFFFAOYSA-N 0.000 description 1
- MRSCJQJTPRRAPR-UHFFFAOYSA-N 3-amino-3-(hydroxymethyl)-1-[4-[4-(5-methyl-1,3-thiazol-2-yl)phenoxy]phenyl]butane-1,4-diol;hydrochloride Chemical compound Cl.S1C(C)=CN=C1C(C=C1)=CC=C1OC1=CC=C(C(O)CC(N)(CO)CO)C=C1 MRSCJQJTPRRAPR-UHFFFAOYSA-N 0.000 description 1
- KXMMTHCAUCFZDI-UHFFFAOYSA-N 4-oxopentanoyl chloride Chemical compound CC(=O)CCC(Cl)=O KXMMTHCAUCFZDI-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- RETIZUJJKZKQFC-UHFFFAOYSA-N CC(C)c1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 Chemical compound CC(C)c1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 RETIZUJJKZKQFC-UHFFFAOYSA-N 0.000 description 1
- HAFUHHGAHSKBGB-UHFFFAOYSA-N CC(NC(CCc(cc1)ccc1Oc(cc1)ccc1-c1ccc(C)[o]1)(CO)CO)=O Chemical compound CC(NC(CCc(cc1)ccc1Oc(cc1)ccc1-c1ccc(C)[o]1)(CO)CO)=O HAFUHHGAHSKBGB-UHFFFAOYSA-N 0.000 description 1
- SVJSJBGRTITEAV-UHFFFAOYSA-N CCC1=SCCC1 Chemical compound CCC1=SCCC1 SVJSJBGRTITEAV-UHFFFAOYSA-N 0.000 description 1
- LJKHPWNLRGEXFS-UHFFFAOYSA-N CCCCc(cc1)ccc1Sc1ccc(C(CC(CO)(CO)N)O)cc1 Chemical compound CCCCc(cc1)ccc1Sc1ccc(C(CC(CO)(CO)N)O)cc1 LJKHPWNLRGEXFS-UHFFFAOYSA-N 0.000 description 1
- BZPGHGMHNGFWPQ-UHFFFAOYSA-N CCCc1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 Chemical compound CCCc1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 BZPGHGMHNGFWPQ-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- MENUPTURPLTOPX-UHFFFAOYSA-N Cc1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 Chemical compound Cc1nc(-c(cc2)ccc2Sc2ccc(C(CC(CO)(CO)N)O)cc2)c[o]1 MENUPTURPLTOPX-UHFFFAOYSA-N 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JHSILQHFEMOXLJ-UHFFFAOYSA-N Cl.OCC(CCCO)(O)C1=CC=C(C=C1)OC1=CC=C(C=C1)C=1SC(=CN1)C Chemical compound Cl.OCC(CCCO)(O)C1=CC=C(C=C1)OC1=CC=C(C=C1)C=1SC(=CN1)C JHSILQHFEMOXLJ-UHFFFAOYSA-N 0.000 description 1
- OJZYNVBZNGPIII-UHFFFAOYSA-N Cl.OCC(CCCO)O Chemical compound Cl.OCC(CCCO)O OJZYNVBZNGPIII-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
- 201000006328 Fanconi syndrome Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 241000639368 Isaria sinclairii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- ZEZJMSRFWGHBQN-UHFFFAOYSA-N NC(CC(c(cc1)ccc1Oc(cc1)ccc1-c1c[o]cn1)O)(CO)CO Chemical compound NC(CC(c(cc1)ccc1Oc(cc1)ccc1-c1c[o]cn1)O)(CO)CO ZEZJMSRFWGHBQN-UHFFFAOYSA-N 0.000 description 1
- KAMOOONXMQDZLP-UHFFFAOYSA-N NC(CC(c(cc1)ccc1Oc(cc1)ccc1-c1ncc[s]1)O)(CO)CO Chemical compound NC(CC(c(cc1)ccc1Oc(cc1)ccc1-c1ncc[s]1)O)(CO)CO KAMOOONXMQDZLP-UHFFFAOYSA-N 0.000 description 1
- MXSBSWCKNINGNP-UHFFFAOYSA-N NC(CC(c(cc1)ccc1Sc(cc1)ccc1-c1c[nH]cn1)O)(CO)CO Chemical compound NC(CC(c(cc1)ccc1Sc(cc1)ccc1-c1c[nH]cn1)O)(CO)CO MXSBSWCKNINGNP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- BTFBEYFQMPGYLB-UHFFFAOYSA-N butane-1,4-diol;hydrochloride Chemical compound Cl.OCCCCO BTFBEYFQMPGYLB-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XRASVXHDSSQFRR-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-(2-butanoyloxyacetyl)phenyl]sulfanylphenyl]-2-oxoethyl]propanedioate Chemical compound CCCC(=O)OCC(=O)c1ccc(Sc2ccc(cc2)C(=O)CC(NC(C)=O)(C(=O)OCC)C(=O)OCC)cc1 XRASVXHDSSQFRR-UHFFFAOYSA-N 0.000 description 1
- SUPDYIXNYKOCLF-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-(2-chloroacetyl)phenoxy]phenyl]-2-oxoethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Oc2ccc(cc2)C(=O)CCl)cc1)(NC(C)=O)C(=O)OCC SUPDYIXNYKOCLF-UHFFFAOYSA-N 0.000 description 1
- HVICOHDASNMVPW-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenoxy]phenyl]-2-oxoethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Oc2ccc(cc2)-c2coc(CC)n2)cc1)(NC(C)=O)C(=O)OCC HVICOHDASNMVPW-UHFFFAOYSA-N 0.000 description 1
- DLOZIGRMLMHRAM-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-[2-(2-methylpropanoyloxy)acetyl]phenoxy]phenyl]ethyl]propanedioate Chemical compound C1=CC(CCC(C(=O)OCC)(NC(C)=O)C(=O)OCC)=CC=C1OC1=CC=C(C(=O)COC(=O)C(C)C)C=C1 DLOZIGRMLMHRAM-UHFFFAOYSA-N 0.000 description 1
- XZDOOBJIRBFWAZ-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-[2-(cyclopropanecarbonyloxy)acetyl]phenoxy]phenyl]-2-oxoethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Oc2ccc(cc2)C(=O)COC(=O)C2CC2)cc1)(NC(C)=O)C(=O)OCC XZDOOBJIRBFWAZ-UHFFFAOYSA-N 0.000 description 1
- ZDWTWIADEZGOOV-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-[4-[4-[2-(cyclopropanecarbonyloxy)acetyl]phenyl]sulfanylphenyl]-2-oxoethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Sc2ccc(cc2)C(=O)COC(=O)C2CC2)cc1)(NC(C)=O)C(=O)OCC ZDWTWIADEZGOOV-UHFFFAOYSA-N 0.000 description 1
- UVQPCGALNNZLSP-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-oxo-2-[4-[4-(2-propanoyloxyacetyl)phenyl]sulfanylphenyl]ethyl]propanedioate Chemical compound CCOC(=O)C(CC(=O)c1ccc(Sc2ccc(cc2)C(=O)COC(=O)CC)cc1)(NC(C)=O)C(=O)OCC UVQPCGALNNZLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- WGYLNYYTGGTJIV-UHFFFAOYSA-N n-[1-hydroxy-2-(hydroxymethyl)-4-[4-[4-(2-propan-2-yl-1,3-oxazol-4-yl)phenoxy]phenyl]butan-2-yl]acetamide Chemical compound O1C(C(C)C)=NC(C=2C=CC(OC=3C=CC(CCC(CO)(CO)NC(C)=O)=CC=3)=CC=2)=C1 WGYLNYYTGGTJIV-UHFFFAOYSA-N 0.000 description 1
- LPFXMKYOUPYAMR-UHFFFAOYSA-N n-[1-hydroxy-2-(hydroxymethyl)-4-[4-[4-(2-propyl-1,3-oxazol-4-yl)phenoxy]phenyl]butan-2-yl]acetamide Chemical compound O1C(CCC)=NC(C=2C=CC(OC=3C=CC(CCC(CO)(CO)NC(C)=O)=CC=3)=CC=2)=C1 LPFXMKYOUPYAMR-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- AZGXHFHVCUHYJE-UHFFFAOYSA-N n-[4-[4-(4-butylphenoxy)phenyl]-1-hydroxy-2-(hydroxymethyl)butan-2-yl]acetamide Chemical compound C1=CC(CCCC)=CC=C1OC1=CC=C(CCC(CO)(CO)NC(C)=O)C=C1 AZGXHFHVCUHYJE-UHFFFAOYSA-N 0.000 description 1
- RMMYJDOCKZCVOZ-UHFFFAOYSA-N n-[4-[4-(4-butylphenyl)sulfanylphenyl]-1-hydroxy-2-(hydroxymethyl)butan-2-yl]acetamide Chemical compound C1=CC(CCCC)=CC=C1SC1=CC=C(CCC(CO)(CO)NC(C)=O)C=C1 RMMYJDOCKZCVOZ-UHFFFAOYSA-N 0.000 description 1
- SNNFFNKSMLWFJH-UHFFFAOYSA-N n-[4-[4-[4-(2-ethyl-1,3-oxazol-4-yl)phenoxy]phenyl]-1-hydroxy-2-(hydroxymethyl)butan-2-yl]acetamide Chemical compound O1C(CC)=NC(C=2C=CC(OC=3C=CC(CCC(CO)(CO)NC(C)=O)=CC=3)=CC=2)=C1 SNNFFNKSMLWFJH-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WEAYWASEBDOLRG-UHFFFAOYSA-N pentane-1,2,5-triol Chemical compound OCCCC(O)CO WEAYWASEBDOLRG-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101882551A CN102863345A (zh) | 2011-07-06 | 2011-07-06 | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN201110188255.1 | 2011-07-06 | ||
| PCT/CN2012/078244 WO2013004190A1 (zh) | 2011-07-06 | 2012-07-05 | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523887A JP2014523887A (ja) | 2014-09-18 |
| JP2014523887A5 true JP2014523887A5 (https=) | 2014-10-30 |
Family
ID=47436521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517431A Pending JP2014523887A (ja) | 2011-07-06 | 2012-07-05 | アミノプロパンジオール誘導体、準備、および医薬品組成物および用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140323501A1 (https=) |
| EP (1) | EP2786982A4 (https=) |
| JP (1) | JP2014523887A (https=) |
| KR (1) | KR20140048239A (https=) |
| CN (2) | CN102863345A (https=) |
| EA (1) | EA201490221A1 (https=) |
| WO (1) | WO2013004190A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014175287A1 (ja) | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| CN104844533B (zh) * | 2014-02-17 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途 |
| WO2020039094A1 (en) * | 2018-08-24 | 2020-02-27 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferative activity |
| IL315313A (en) * | 2018-08-24 | 2024-10-01 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
| CN111087356B (zh) * | 2018-10-24 | 2022-06-21 | 中国医学科学院药物研究所 | 一种艾托莫德的制备方法 |
| CN111087358B (zh) * | 2018-10-24 | 2022-06-21 | 中国医学科学院药物研究所 | 普赛莫德的制备方法 |
| CN111087359B (zh) * | 2018-10-24 | 2022-06-21 | 中国医学科学院药物研究所 | 艾托莫德的制备方法 |
| CN115974803B (zh) * | 2022-12-12 | 2024-04-09 | 渐宽(苏州)生物科技有限公司 | 一种普赛莫德的晶型及其制备方法和用途 |
| CN116217507B (zh) * | 2022-12-22 | 2024-12-20 | 渐宽(苏州)生物科技有限公司 | 一种艾托莫德的晶型及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| DE60235900D1 (de) * | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| CA2461212C (en) * | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| BR0311347A (pt) * | 2002-05-27 | 2005-02-22 | Novartis Ag | Alcanóis bis-aromáticos |
| JP4571497B2 (ja) * | 2002-09-19 | 2010-10-27 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| WO2005014525A2 (en) * | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
| WO2005044780A1 (ja) * | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| WO2006041015A1 (ja) * | 2004-10-12 | 2006-04-20 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| JP2007001921A (ja) * | 2005-06-23 | 2007-01-11 | Kyorin Pharmaceut Co Ltd | アミノスルホン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| EP2066800A2 (en) * | 2006-08-04 | 2009-06-10 | Decode Genetics EHF | Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation |
| CA2659598A1 (en) * | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Amino phosphate derivative and s1p receptor modulator having same as an active ingredient |
| WO2008099781A1 (ja) * | 2007-02-13 | 2008-08-21 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 |
| TW200946105A (en) * | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| WO2009142194A1 (ja) * | 2008-05-19 | 2009-11-26 | 杏林製薬株式会社 | 光学活性アミノアルコール誘導体の製造方法 |
| JP2010013407A (ja) * | 2008-07-04 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体 |
| JP2010077053A (ja) * | 2008-09-25 | 2010-04-08 | Kyorin Pharmaceut Co Ltd | フェノール誘導体及びそれらを有効成分とする医薬 |
| AU2009304596A1 (en) * | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| HRP20141065T1 (hr) * | 2009-07-09 | 2015-02-13 | Kyorin Pharmaceutical Co., Ltd. | Derivati difenil-sulfida i lijekovi koji ih sadrže kao aktivni sastojak |
| JP2011032226A (ja) * | 2009-08-03 | 2011-02-17 | Kyorin Pharmaceutical Co Ltd | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
-
2011
- 2011-07-06 CN CN2011101882551A patent/CN102863345A/zh active Pending
-
2012
- 2012-07-05 EA EA201490221A patent/EA201490221A1/ru unknown
- 2012-07-05 WO PCT/CN2012/078244 patent/WO2013004190A1/zh not_active Ceased
- 2012-07-05 CN CN201280032727.7A patent/CN103702973B/zh active Active
- 2012-07-05 US US14/130,861 patent/US20140323501A1/en not_active Abandoned
- 2012-07-05 EP EP12808109.8A patent/EP2786982A4/en not_active Withdrawn
- 2012-07-05 KR KR1020147003101A patent/KR20140048239A/ko not_active Ceased
- 2012-07-05 JP JP2014517431A patent/JP2014523887A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523887A5 (https=) | ||
| CN103702973B (zh) | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| CN102264693B (zh) | 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物 | |
| KR20040017227A (ko) | 엔-아릴페닐아세트아미드 유도체 및 이를 함유하는약제학적 조성물 | |
| AU662073B2 (en) | Substituted cyclohexane derivatives, processes for their preparation and the use of the compounds for treating diseases | |
| KR20150013527A (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
| KR20140000275A (ko) | 인체 면역결핍 바이러스에 대해 항체 모집 및 진입 저해 활성을 갖는 2작용기의 분자 | |
| WO2006090817A1 (ja) | インドール化合物およびその用途 | |
| CN102260177A (zh) | 丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| CA2949663A1 (en) | Dipicolylamine derivatives and their pharmaceutical uses | |
| CN104844486B (zh) | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| CN102225896B (zh) | 大黄酸的醚衍生物以及它们的治疗用途 | |
| JPS63258854A (ja) | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 | |
| KR102352728B1 (ko) | 트리글리세라이드, 총 콜레스테롤, 및 저밀도 지단백질의 혈중농도를 감소시키는 방법 | |
| JP6906444B2 (ja) | 疾患および状態を処置するための組成物および方法 | |
| CA2289517A1 (en) | Novel sulfonamide derivatives | |
| JP2012097003A (ja) | ビキシン誘導体及び細胞保護剤 | |
| EA017927B1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| CN102260178A (zh) | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| JPWO2008032665A1 (ja) | 新規フェニル酢酸誘導体 | |
| CN101386580A (zh) | 氨基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| EP1844775B1 (en) | Therapeutic agent for the treatment of herpes progenitalis after development of lesions | |
| RU2602500C2 (ru) | (z)-3-(2-оксо-2-(4-толил)этилиден)пиперазин-2-он, обладающий противовоспалительной и/или антиноцицептивной активностью, способ его получения, фармацевтические композиции | |
| CN102040603A (zh) | 溴化n-邻甲氧羰基苄基四氢小檗碱及其治疗高血脂症的用途 | |
| KR101172472B1 (ko) | 4급 암모늄 화합물, 그 제조 방법, 뇌혈관 장애 치료제 및 심장 질환 치료제 |